Kidney Cancer Coverage From Every Angle
Advertisement
Advertisement

Published Medical Literature

Does Long Noncoding RNA Signature Have Prognostic Value in Kidney Cancer?
Bevacizumab Plus Immune Checkpoint Inhibition in Renal Cell Carcinoma
Identifying Renal Transplant Patients at Risk for Squamous Cell Carcinoma by DNA Methylation of T Cells
Metastatic Renal Cell Carcinoma: Sunitinib Alone Versus Nephrectomy
Targeting Metastases in Renal Cell Carcinoma With Stereotactic Radiation
Prevalence of Germline Mutations in Patients With Renal Cell Carcinoma
Distinguishing Subtypes of Kidney Cancer With Histologic Overlap
Lymph Node Dissection and Survival in High-Risk Kidney Cancer
Impact of Biopsychosocial Distress on Outcomes in Metastatic Kidney Cancer
Is There a Long-Term Benefit to TKIs Before Cytroreductive Nephrectomy?
Is Partial Nephrectomy Underused in Younger Patients With cT1 Renal Masses?
Identifying Risk Factors for Recurrence of Nonmetastatic Renal Cell Carcinoma
Relative Dose Intensity in First-Line Sunitinib Therapy for Metastatic Kidney Cancer
Is Neutrophil-Lymphocyte Ratio Predictive of Outcome After Surgery for Metastatic Kidney Cancer?
Potential Biomarker of Response to Sunitinib in Metastatic Kidney Cancer
Outcome Differences Based on Histopathology in Renal Cell Carcinoma
Tumor-Targeted Strategy for Overcoming Chemoresistance in Kidney Cancer
Health-Related Quality of Life With Pembrolizumab for Advanced Urothelial Cancer
Early Landmark Events for Patients Diagnosed With Clear Cell Renal Cell Carcinoma
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Timing of Sunitinib Schedule in Patients With Metastatic Renal Cell Carcinoma
Comparison of Nivolumab/Ipilimumab and Sunitinib in Advanced Kidney Cancer
DDR Genes and Response to Checkpoint Blockade in Urothelial Cancer
SABR as an Alternative to Cytoreductive Nephrectomy for Inoperable Kidney Cancer
Predicting Disease Recurrence in Localized Clear Cell Kidney Cancer
Genomic Alterations in Clear Cell Renal Cell Carcinoma and Response to Immune Checkpoint Inhibitors
Gene Discovery May Shed Light on Mechanism of Immunotherapy Resistance
Long-Term Outcomes With Atezolizumab in Metastatic Urothelial Carcinoma
Axitinib Plus Pembrolizumab in Advanced Kidney Cancer
METEOR Trial: Quality-of-Life Outcomes in Metastatic Kidney Cancer
Novel Diagnostic Technique for Clear Cell Renal Cell Carcinoma
Cost Sharing and Targeted Therapy Among Older Patients With Kidney Cancer
Crizotinib May Provide Disease Control in Advanced Papillary Renal Cell Carcinoma
Avelumab as Second-Line Treatment for Advanced Urothelial Carcinoma
Cabozantinib Versus Everolimus for Bone Metastases From Renal Cell Carcinoma
Familial Clustering of Bladder Cancer Regardless of Smoking History
Managing Cabozantinib-Related Adverse Events in Patients With Renal Cell Carcinoma
Novel Drug for Treatment of Advanced Clear Cell Renal Cell Carcinoma
Is Physical Inactivity an Independent Risk Factor for Renal Cancer?
Stereotactic Ablative Radiation for Renal Tumors
Renal Function With Ablative Techniques for Renal Mass in Solitary Kidney
miR-181a Upregulation and KLF6 Expression in Clear Cell Renal Cell Carcinoma
Recovery of Long-Term Renal Function After Radical Nephrectomy
Therapeutic Implications of Histologic Subtypes in Papillary Renal Cell Carcinoma
Perioperative Blood Transfusion and Prognosis After Surgery for Renal Cancer
Robotic-Assisted Surgery for Radical Nephrectomy: Outcomes and Costs
Potential Molecular Biomarker in Clear Cell Kidney Cancer
Activity and Safety of Tivozanib in Advanced Renal Cell Carcinoma
Post-Progression Response to Nivolumab in Advanced Renal Cell Carcinoma
Adjuvant Pazopanib After Surgery for Locally Advanced Renal Cell Carcinoma
Multigene Panel Testing in Identifying Hereditary Kidney Cancer
Bevacizumab Plus Novel Monoclonal Antibody in Metastatic Kidney Cancer
Sequence of Everolimus and Sunitinib in Metastatic Renal Cell Carcinoma
Can Dynamic Changes During Therapy Predict Survival in Renal Cell Cancer?
Predictive Marker in Nonmetastatic Renal Cell Carcinoma After Nephrectomy
Impact of Margin Status on Survival After Radical Nephrectomy
ALK Inhibitor MK-2206 Versus Everolimus in Refractory Renal Cell Carcinoma
Thyroid Dysfunction in Patients Receiving Immunotherapy for Advanced Kidney Cancer
Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma
Timing of Treatment for Advanced Kidney Cancer
Treatment Outcomes Based on Ethnicity in Metastatic Renal Cell Carcinoma
Combining Nephrectomy and SBRT for Advanced Kidney Cancer
MET Inhibitor Savolitinib in Advanced Papillary Renal Cell Cancer
Pembrolizumab as Second-Line Treatment for Advanced Urothelial Carcinoma
Impact of Everolimus-Induced Pneumonitis on Metastatic Renal Cell Carcinoma
Intermittent Sunitinib in Previously Untreated Metastatic Renal Cell Carcinoma
Vinflunine Maintenance in Advanced Urothelial Carcinoma
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer
Targeted Therapies for Metastatic Chromophobe Renal Cell Carcinoma
Alternating Treatment Regimens in Clear Cell Renal Cell Cancer
Use of Metformin in Patients With Metastatic Renal Cell Carcinoma
Complete Surgical Metastasectomy in Metastatic Renal Cell Carcinoma
Pazopanib vs Paclitaxel in Advanced Urothelial Carcinoma
Potential Biomarker in Metastatic Renal Cell Carcinoma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.